NeoRes Study - Preoperative Chemotherapy in Colorectal Peritoneal Disease Prior to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Launched by UPPSALA UNIVERSITY · Mar 24, 2025
Trial Information
Current as of April 26, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • HIPEC MDK where extensive isolated peritoneal metastases are noted
- • Colorectal cancer
- • Decision during HIPEC MDT to start systemic conversion chemotherapy
- Exclusion Criteria:
- • Appendiceal cancer
- • Retroperitoneal lymph node metastases
- • Other systemic metastases (e.g. liver, lung, brain, bone etc)
About Uppsala University
Uppsala University, a prestigious institution located in Sweden, is renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, the university leverages its extensive expertise in various fields of health sciences to conduct innovative studies aimed at improving patient outcomes and understanding complex diseases. With a strong emphasis on ethical standards and rigorous scientific methodologies, Uppsala University collaborates with a network of researchers, healthcare professionals, and industry partners to facilitate groundbreaking clinical trials that contribute to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Uppsala, , Sweden
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported